肝硬化合并肝细胞癌患者接受治愈性挽救性肝移植:一项意向性治疗分析
研究纳入1994至2012年110例初始可切除且可移植的肝硬化肝细胞癌患者,采用挽救性肝移植策略并行意向性治疗分析。63例(57%)切除后复发,其中30例可完成挽救性肝移植(复发可移植率48%)。自初次切除起,意向性治疗5年总生存率和无病生存率分别为69%和60%;该策略仅在56%患者中达到治愈。
要点
- 挽救性肝移植策略在110例可切除且可移植的肝硬化肝细胞癌患者中,意向性治疗5年总生存率69%、无病生存率60%。
- 63例(57%)初次切除后复发,其中30例成功行挽救性肝移植,复发可移植率为48%。
- 多因素分析显示,策略开始时MELD评分>10及未行新辅助TACE是策略成功的预测因素。
核心结论
- 挽救性肝移植策略仅在56%的病例中达到治愈。
- 策略开始时较高的MELD评分及切除前未行TACE是挽救性肝移植策略成功的预测因素。
研究设计与样本
- 1994年至2012年,所有初始可切除且可移植的肝硬化肝细胞癌患者纳入挽救性肝移植策略。
- 共纳入110例患者,采用意向性治疗分析评估该策略的结局及成功预测因素。
主要发现
- 63例患者(57%)在初始切除后出现肿瘤复发,其中30例能够实施挽救性肝移植(复发可移植率=48%)。
- 自初次切除起,意向性治疗5年总生存率为69%,无病生存率为60%。
- 挽救性肝移植策略在60例患者(56%)中成功,其中36%仅通过切除 alone 成功,19%通过复发后挽救性肝移植成功。
- 多因素分析中,切除前成功预测因素包括MELD评分>10及未行新辅助TACE。
- 切除后额外预测因素包括无切除后并发症及切除标本T分期为1-2期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The salvage liver transplantation (SLT) strategy was conceived for initially resectable and transplantable (R&T) hepatocellular carcinoma (HCC) patients, to try to obviate upfront liver transplantation, with the "safety net" of SLT in case of postresection recurrence. The SLT strategy is successful or curative when patients are recurrence free following primary resection alone, or after SLT for recurrence. The aim of the current study was to determine the SLT strategy's potential for cure in R&T HCC patients, and to identify predictors for its success. From 1994 to 2012, all R&T HCC patients with cirrhosis were enrolled in the SLT strategy. An intention-to-treat (ITT) analysis was used to determine this strategy's outcomes and predictors of success according to the above definition. In total, 110 patients were enrolled in the SLT strategy. Sixty-three patients (57%) had tumor recurrence after initial resection, and in 30 patients SLT could be performed (recurrence transplantability rate = 48%). From the time of initial resection, ITT 5-year overall and disease-free survival rates were 69% and 60%, respectively. The SLT strategy was successful in 60 patients (56%), either by resection alone (36%), or by SLT for recurrence (19%). Preresection predictors of successful SLT strategy at multivariate analysis included Model for End-Stage Liver Disease (MELD) score >10, and absence of neoadjuvant transarterial chemoembolization (TACE). Additional postresection predictive factors were absence of postresection morbidity, and T-stage 1-2 at the resection specimen. CONCLUSION: The SLT strategy is curative in only 56% of cases. Higher MELD score at inception of the strategy and no pre-resection TACE are predictors of successful SLT strategy. (Hepatology 2018;67:204-215).
引用
- de Haas RJ, Lim C, Bhangui P, et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology. 2017. PMID: 28806477. doi:10.1002/hep.29468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。